BiotechTube

Tacrolimus immediate-release formulation + Tacrolimus prolonged-release formulation + Induction therapy + Mycophenolic acid drugs + Corticosteroids

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Kidney Transplant

Conditions

Kidney Transplant

Trial Timeline

Oct 21, 2018 → Jul 15, 2022

NCT ID
NCT03644485

About Tacrolimus immediate-release formulation + Tacrolimus prolonged-release formulation + Induction therapy + Mycophenolic acid drugs + Corticosteroids

Tacrolimus immediate-release formulation + Tacrolimus prolonged-release formulation + Induction therapy + Mycophenolic acid drugs + Corticosteroids is a approved stage product being developed by Astellas Pharma for Kidney Transplant. The current trial status is completed. This product is registered under clinical trial identifier NCT03644485. Target conditions include Kidney Transplant.

What happened to similar drugs?

20 of 20 similar drugs in Kidney Transplant were approved

Approved (20) Terminated (1) Active (0)
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅TacrolimusAstellas PharmaApproved
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
✅Tacrolimus granulesAstellas PharmaApproved
✅MMF (Cellcept) and Steroids + Tacrolimus (Prograf)Astellas PharmaApproved
✅Advagraf + Mycophenolate Mofetil + Simulect + CorticosteroidsAstellas PharmaApproved
✅tacrolimusAstellas PharmaApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03644485ApprovedCompleted

Competing Products

20 competing products in Kidney Transplant

See all competitors
ProductCompanyStageHype Score
Empagliflozin + Matching placeboEli LillyPhase 3
40
Baricitinib + PlaceboEli LillyPhase 2
35
SGLT2 inhibitorEli LillyPre-clinical
30
LY2623091 + EplerenoneEli LillyPhase 2
35
Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
39
TacrolimusAstellas PharmaApproved
35
RituximabAstellas PharmaPhase 2
35
Prograf + MR4Astellas PharmaPhase 3
40
basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
43
Tacrolimus, modified releaseAstellas PharmaPhase 3
40
Tacrolimus granulesAstellas PharmaApproved
43
roxadustatAstellas PharmaPhase 3
40
ASP1128 + PlaceboAstellas PharmaPhase 2
35
FK506MR + Prograf + Mycophenolate Mofetil + Methylprednisolone + PrednisoloneAstellas PharmaPhase 3
40
MMF (Cellcept) and Steroids + Tacrolimus (Prograf)Astellas PharmaApproved
43
ASP1585Astellas PharmaPhase 3
40
Alefacept + tacrolimus + basiliximab + mycophenolate mofetil + CorticosteroidsAstellas PharmaPhase 2
35
Advagraf + Mycophenolate Mofetil + Simulect + CorticosteroidsAstellas PharmaApproved
43
tacrolimusAstellas PharmaApproved
39
roxadustatAstellas PharmaPhase 3
40